Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who suffered losses exceeding $100,000 during the specified class period to seek legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - The defendants are accused of making misleading statements regarding the reliability and functionality of the G6 and G7 devices, which led to increased regulatory scrutiny and potential financial harm to the company [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - To participate in the class action, investors can visit the provided link or contact the firm directly for more information [3][6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption [6][7]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [7]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [8]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [9].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - Defendants allegedly made unauthorized design changes to the G6 and G7 systems that compromised their reliability and safety [2]. - The enhancements claimed for the G7 device were reportedly overstated, leading to potential health risks for users relying on these devices for accurate glucose readings [2]. - DexCom is accused of downplaying the severity of issues related to the G7 devices, which could result in increased regulatory scrutiny and significant legal and financial repercussions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the enhancements to the G7 device were overstated, and the true scope of issues related to the G7 devices was downplayed by the defendants [5]. - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [5].

Group 1: Retail Sector - Ulta Beauty (ULTA) shares surged nearly 13% after reporting better-than-expected earnings and raising its full-year forecasts, driven by resilient demand in the beauty category, increased transactions, and the acquisition of British luxury cosmetics firm Space NK [4][9] - Dollar-store operators Dollar Tree (DLTR) and Dollar General (DG) saw their shares rise about 6% following strong earnings reports, indicating traction among customers from various income levels seeking deals [7][9] Group 2: Healthcare Sector - Moderna (MRNA) stock jumped close to 9% after a long-term study in France indicated that its COVID-19 vaccine is safe and effective, showing a 75% lower risk of dying from COVID-19 for vaccinated individuals compared to the unvaccinated [5][9] - Cooper Companies (COO) exceeded quarterly earnings forecasts and provided an optimistic outlook, with shares climbing around 6% following the announcement of a strategic review aimed at simplifying its business [6][9] Group 3: Media and Entertainment Sector - Netflix (NFLX) agreed to acquire Warner Bros. Discovery's studio and streaming business in an $83 billion deal, impacting shares of Paramount Skydance (PSKY) which fell nearly 10% as a result of the competitive bidding landscape [8][9] - Warner Bros. Discovery's stock climbed more than 6% following the acquisition announcement, while Netflix shares slipped about 3% [8][9] Group 4: Market Overview - Major U.S. equities indexes moved higher after a key inflation report came in lower than anticipated, with the S&P 500 and Dow edging 0.2% higher and the Nasdaq rising 0.3% [3][9]

Fred Moll, the cofounder of $200 billion Intuitive Surgical, has invested in some 15 companies building robots that could help make both complex and common surgeries more accessible to everyone. https://t.co/nfhU0uB59w https://t.co/gDtwdwakgj ...

Core Viewpoint - Meihua International Medical Technologies Co., Ltd. is facing delisting from Nasdaq due to non-compliance with listing rules, specifically failing to maintain a minimum bid price and the required number of publicly held shares [1][5]. Group 1: Delisting Details - On December 2, 2025, Nasdaq notified Meihua of the delisting determination due to failure to regain compliance with Listing Rule 5550(a)(2) [1]. - The company was previously informed on December 3, 2024, that its share price had been below $1 for 30 consecutive business days, violating Listing Rule 5450(a)(1) [2]. - Meihua executed a reverse share split of 1:16 on November 24, 2025, but did not meet the $1.00 minimum bid price requirement for 10 consecutive business days before December 1, 2025 [3]. Group 2: Compliance and Appeal - The company was given until December 9, 2025, to appeal the delisting decision, and it submitted a hearing request on December 4, 2025 [4]. - As of December 1, 2025, Meihua was also found to have less than 500,000 publicly held shares, which is another basis for delisting under Listing Rule 5550(a)(4) [5]. Group 3: Company Overview - Meihua International Medical Technologies Co., Ltd. manufactures and provides Class I, II, and III disposable medical devices, with over 1,000 types of products for domestic sales and more than 120 products exported to over 30 countries [6]. - The company has received international "CE" certification and ISO 13485 system certification, and is registered with the FDA for over 20 Class I products [6].

NEW YORK, Dec. 5, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.So what: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form-2 ...

WHAT'S NEXT? If you suffered a loss in Inspire Medical Systems, Inc. during the relevant time frame, you have until January 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team ...